Epithelioid inflammatory myofibroblastic sarcoma responsive to surgery and an ALK inhibitor in a patient with panhypopituitarism

Intern Med. 2014;53(19):2211-4. doi: 10.2169/internalmedicine.53.2546.

Abstract

We encountered a case of epithelioid inflammatory myofibroblastic sarcoma (EIMS) originating from an abdominal organ that rapidly regrew twice. The patient underwent two surgeries. Large tumors grew within three months after the second surgery. The patient subsequently received chemotherapy with an anaplastic lymphoma kinase (ALK) inhibitor. Although EIMS has a poor prognosis, the patient continues to be alive with disease 14 months after surgical treatment and the administration of the ALK inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Colonoscopy
  • Combined Modality Therapy
  • Enzyme Inhibitors / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Hypopituitarism / complications*
  • Hypopituitarism / diagnosis
  • Intestinal Neoplasms / complications
  • Intestinal Neoplasms / diagnosis
  • Intestinal Neoplasms / therapy*
  • Intestine, Small
  • Laparotomy / methods*
  • Male
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Sarcoma / complications
  • Sarcoma / diagnosis
  • Sarcoma / therapy*
  • Tomography, X-Ray Computed
  • Young Adult

Substances

  • Enzyme Inhibitors
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases

Supplementary concepts

  • Combined Pituitary Hormone Deficiency